Phaseline

Targets › ITGAL

ITGAL (Integrin alpha-L): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 3; Oncology, Ophthalmology; next expected readout Nov 2038.

Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R. Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes…. (UniProt, P20701)

Open in Phaseline: the race on ITGAL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lunan Better PharmaceuticalLifitegrast
Integrin alpha-L/beta-2 (LFA-1) antagonist
ITGAL, ITGB2Phase 3Dry Eye Disease (DED)–
Seattle Children's HospitalPatient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T ce
CD171-targeting CAR-T cells with 4-1BB:zeta costimulation
ITGALPhase 1NeuroblastomaNov 2038

Conditions

Neuroblastoma (3) Dry Eye Disease (DED) (1)

Modalities

other (1)

Companies

Seattle Children's Hospital (1) Lunan Better Pharmaceutical (1)

Related targets

ITGB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.